Related Experiment Video
Updated: Mar 1, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Exploring SLC1A5 (ASCT2), SLC7A5, and SLC3A2 (LAT1) Genetic Variants in Colorectal Cancer: Implications for Prognosis
Catarina Lopes1,2,3, Catarina Macedo-Silva4, Mónica Farinha5
1Precancerous Lesions and Early Cancer Management Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Group), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Porto, Portugal; catarina.p.lopes@ipoporto.min-saude.pt.
Background/Aim:
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide, with up to 20% of patients presenting with metastatic disease at diagnosis. The clinical relevance of amino acid transporters ASCT2 and LAT1 in CRC, particularly Caucasian populations, remains underexplored. This study evaluates the prognostic impact of single nucleotide polymorphisms (SNPs) in the genes encoding these transporters (SLC1A5, SLC7A5, and SLC3A2) in a European population.
Patients And Methods:
A total of 212 patients with CRC were included, with a median follow-up of 89 months. A tagSNP approach was applied to select 28 SNPs, genotyped using MassARRAY® iPLEX Gold Technology. Kaplan-Meier analysis, log-rank tests, and Cox proportional-hazards models were used to assess the association between SNPs and overall survival (OS). Multivariate models adjusted for clinicopathological covariates.
Results:
Five tagSNPs were significantly associated with CRC prognosis. Specifically, SLC1A5 rs1862335 (p=0.040), SLC7A5 rs1060253 (p=0.022), and SLC3A2 rs12804553 (p=0.029) and rs2070870 (p=0.021) significantly affected five-year OS. In multivariate analysis, carriers of the SLC1A5 rs1862553 G allele had increased mortality risk [hazard ration (HR)=1.88, 95% confidence interval (CI)=1.09-3.23, p=0.022), as did carriers of the SLC3A2 rs12804553/rs2070870 T/C alleles (HR=2.22, 95%CI=1.24-3.99, p=0.007). Individuals harboring all three risk alleles had a 2.3-fold increased risk of death (HR=2.27, 95%CI=1.24-4.14, p=0.008).
Conclusion:
Genetic variants in ASCT2 and LAT1-related genes are independently associated with survival in CRC, supporting the growing body of evidence supporting personalized medicine and highlighting the need to consider both genetic and tumor heterogeneity when defining risk and tailoring treatment strategies.
More Related Videos
Related Concept Videos
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

